BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy

Authors:
  • AFA. Font
    A. Font
  • MTM. Tarón
    M. Tarón
  • CCC. Costa
    C. Costa
  • LLL. Layos
    L. Layos
  • LPL. Pérez-Roca
    L. Pérez-Roca
  • JSJ. Sánchez
    J. Sánchez
  • ICI. Chaib
    I. Chaib
  • MMM. Mora
    M. Mora
  • JGJ. Gago
    J. Gago
  • RRR. Rosell
    R. Rosell
Publisher website
Google Scholar
Abstract
5021 Background: In p with locally-advanced bladder cancer, neoadjuvant chemotherapy followed by cystectomy improves survival compared to surgery alone, especially in p attaining a pathological response (pT0–1N0M0). However, at present no clinical markers are available to predict response to chemotherapy in bladder cancer. BRCA1 mRNA expression has been associated with chemosensitivity and survival in lung and ovarian cancer p (Taron et al. 2004; Quinn et al. 2007) and could be a useful predictive marker in bladder cancer as well. Methods: We analyzed BRCA1 mRNA expression by quantitative PCR in tumor biopsies obtained by transurethral resection from 51 p with locally-advanced bladder cancer. 44 p were clinically staged as cT3–4N0M0, 5 p had regional lymph nodes (cTxN+), and 2 p had distant lymph nodes. 35 p received cisplatin, methotrexate plus vinblastine; 16 p were treated with gemcitabine plus cisplatin. Results: After a median of 3 cycles of chemotherapy, cystectomy was performed in 49 p (96%). A sig...